by Madaline Spencer | Jul 9, 2024
The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Follicular lymphoma is a form of...
by Madaline Spencer | Jul 9, 2024
Diane Schriner, Vice President of Erdheim-Chester Disease Global Alliance, provides an overview of Erdheim-Chester disease (ECD). ECD is a rare blood cancer characterized by the overproduction of histiocytes, which then accumulate in tissues and organs....
by Madaline Spencer | Jul 7, 2024
Robert Califf, MD, Commissioner of the U.S. Food and Drug Administration (FDA), discusses some of the challenges that the agency faces in regards to rare diseases. Dr. Califf notes how important it is that the FDA ensures the efficacy and safety of new...
by Madaline Spencer | Jul 2, 2024
Andra Stratton, President and Co-founder of Lipodystrophy United, discusses the challenges of lipodystrophy from a patient’s perspective. Lipodystrophies are rare metabolic disorders characterized by the loss of adipose tissue. This leads to complications such...
by Madaline Spencer | Jul 1, 2024
Márcia Waddington-Cruz, MD, PhD, Federal University of Rio de Janeiro, discusses a Phase 3 trial testing eplontersen in adult patients with hereditary transthyretin polyneuropathy. Hereditary transthyretin amyloidosis (hATTR) is a rare genetic condition...
